This week in drug discovery (24-28 March)
News round-up for 24-28 March by DDW Senior Digital Content Editor Diana Spencer.
Weight loss drugs have been making the news this week. As we come to the end of Women’s History Month, two of the reported studies focus on women’s health, specifically the role of weight loss drugs in treating endometriosis and why women have worse side effects from these therapeutics.
The top stories:
GLP-1 implant NPM-115 enters clinical trials for obesity
Vivani Medical has announced the successful administration of its first GLP-1 (exenatide) implant in the LIBERATE-1 clinical trial.
Mounjaro’s role in managing endometriosis
Endometriosis is a chronic and often debilitating condition affecting one in 10 women in the UK. Weight management and metabolic health play an essential role in symptom control.
Study reveals insights into GLP-1 drug effectiveness across sexes
A new study has uncovered fundamental sex-based differences in how weight loss medications interact with human biology, revealing why women experience more severe side effects from GLP-1 drugs such as Ozempic and Zepbound.
Closed Loop Medicine secures US patents for GLP-1 therapies
Closed Loop Medicine has been granted US patents covering advancements in GLP-1 therapies for obesity and diabetes, and direct oral anticoagulants (DOACs) for cardiovascular health.
First-in-class GIP antagonist for obesity enters Phase I trials
Helicore Biopharma has reported dosing the first participant in its Phase I study of HCR-188 for the treatment of obesity.